Histologic Considerations in Post-Neoadjuvant Pathologic Assessment of Breast Cancer: Implications for Residual Disease Measurement and Response Interpretation

Histologic growth patterns can make established post-neoadjuvant assessment rules difficult to apply and can complicate the interpretation of response evidence. This narrative review connects these issues by identifying how residual architecture affects measurement and how histologic and endpoint definitions shape clinical interpretation. Reporting standards and selected clinicopathologic studies, principally of chemotherapy-based treatment, are integrated. Pathologic complete response (pCR), post-treatment pathologic tumor–node–metastasis classification (ypTNM), and residual cancer burden (RCB) capture distinct aspects of residual disease. Invasive lobular carcinoma may leave a broad, low-cellularity infiltrate, whereas persistent extracellular mucin can exaggerate apparent viable burden. These patterns require spatial reconstruction, distinction between the largest contiguous invasive focus and the RCB tumor bed, and reconciliation of nodal and lymphovascular findings. Metaplastic breast carcinoma and study-defined triple-negative apocrine carcinoma illustrate a second problem: differences in observed pCR frequency need to be interpreted alongside the regimen, histologic criteria, endpoint definition, and analyzed population. This review separates response occurrence, incremental prognostic value, response–outcome modification, and treatment benefit modification, specifying the evidence required for each. This approach connects the practical specimen assessment with clinically interpretable evidence while retaining established response definitions.